Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm AB-BNCT with NBB-001 and NBB-002 for recurrent head and neck malignancies
CTR20261081Phase 2Active
- Sponsor
- Zhongpeng Pharmaceutical
- Start
- Mar 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of boronophenylalanine + fructose, 18F-fluoroboronophenylalanine in head and neck cancer (HNC), sponsored by Zhongpeng Pharmaceutical. Started Mar 2026; status: active.
02
Drugs
boronophenylalanine + fructose18F-fluoroboronophenylalanine
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on CTR20261081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261081.